Pajares A, Vicente R, Larrea L, Vicente J L, Barberá M
Servicio de Anestesiología y Reanimación, Hospital Universitario La Fe, Valencia, España.
Rev Esp Anestesiol Reanim. 2012 Mar;59(3):150-6. doi: 10.1016/j.redar.2012.02.033. Epub 2012 May 3.
On of the most common, and serious, complications in cardiac surgery is postoperative bleeding. According to the majority of studies, between 10% and 92% of patients subjected to elective surgery require transfusions of blood products and blood derivatives. Transfusions and reinterventions are associated with longer stays in critical care units and a decrease in survival rates. There have been some important changes in the treatment of changes in haemostasis and post-surgical bleeding in the last few years, particularly with the introduction into clinical practice of working procedures backed up by clinical guidelines, as well as the appearance of new drugs. The aim of this work is to describe the main characteristics and update the use of prothrombin complexes that are currently available in Spain, with special emphasis on their use in cardiac surgery.
心脏手术中最常见且严重的并发症之一是术后出血。根据大多数研究,接受择期手术的患者中有10%至92%需要输注血液制品和血液衍生物。输血和再次干预与在重症监护病房停留时间延长以及生存率降低有关。在过去几年中,止血和术后出血治疗方面发生了一些重要变化,特别是随着临床指南支持的工作程序引入临床实践以及新药的出现。这项工作的目的是描述目前在西班牙可用的凝血酶原复合物的主要特征并更新其使用情况,特别强调其在心脏手术中的应用。